<DOC>
	<DOC>NCT01229462</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.</brief_summary>
	<brief_title>Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Openangle glaucoma or ocular hypertension in at least one eye that is not responsive to topical beta blockers No anticipated wearing of contact lenses during study Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye) Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months Required regular use of other ocular medications except for occasional use of artificial tears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>